Home » FDA: Prilosec Reduces Plavix’s Effectiveness
FDA: Prilosec Reduces Plavix’s Effectiveness
The FDA is requiring a labeling change to Sanofi-Aventis
and Bristol-Myers Squibb’s blockbuster anti-blood-clotting drug Plavix to indicate that
it should not be used with AstraZeneca’s stomach-acid treatment Prilosec and some other acid-reducing drugs. An FDA-requested study done by Sanofi
found that Prilosec (omeprazole) reduced the anti-blood-clotting effect of Plavix (clopidogrel) by almost half when the two medicines were given to the
same patient, the FDA says in a public health advisory Tuesday.
Drug Industry Daily
Drug Industry Daily
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May